Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-11-28
2006-11-28
Mertz, Prema (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388230, C424S130100, C424S139100, C424S145100
Reexamination Certificate
active
07141653
ABSTRACT:
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human anti-IL-5 antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IL-5 antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IL-5 antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IL-5 antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
REFERENCES:
patent: 5096704 (1992-03-01), Coffman et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5591669 (1997-01-01), Krimpenfort et al.
patent: 5612205 (1997-03-01), Kay et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5643763 (1997-07-01), Dunn et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5683892 (1997-11-01), Ames, Jr. et al.
patent: 5721367 (1998-02-01), Kay et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5877293 (1999-03-01), Adair et al.
patent: 5886152 (1999-03-01), Nakatani et al.
patent: 5916771 (1999-06-01), Hori et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5985615 (1999-11-01), Jakobovits et al.
patent: 5994619 (1999-11-01), Stice et al.
patent: 5998209 (1999-12-01), Jokobovits et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6091001 (2000-07-01), Jakobovits et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6129913 (2000-10-01), Ames et al.
patent: 6130364 (2000-10-01), Jakobovits et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 2002/0142374 (2002-10-01), Gallo et al.
patent: 0 267 779 (1988-05-01), None
patent: 0 367 596 (1990-05-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 93/06213 (1993-04-01), None
patent: WO 93/16184 (1993-08-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 98/16654 (1998-04-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 99/45031 (1999-09-01), None
patent: WO 99/53049 (1999-10-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/37504 (2000-06-01), None
patent: WO 01/62287 (2001-08-01), None
Panka et al. Proc. Natl. Acad. Sci. USA vol. 85, pp. 3080-3084 (May 1988).
Rudikoff et al. Proc. Natl. Acad. Sci. USA vol. 79, pp. 1979-1983 (Mar. 1982).
Amit et al. Science, vol. 233, pp. 747-753, (Aug. 1986).
International Search Report for International Application No. PCT/US03/09260.
Bird et al., Science 242:423-426 (1988).
Egan et al., Arzneim.-Forsch./Drug Res. 49(II),Nr. 9:779-790 (1999).
Egan et al., Int. Arch Allergy Immunol 107(1-3):321-322 (1995).
Fanger et al., Immunomethods 4:72-81 (1994).
Galfre et al., Methods in Enzymology 73:3-46 (1981).
Green et al., J Exp Med 188(3):483-495 (1998).
Green et al., Nature Genetics 7:13-21 (1994).
Greenfeder et al., Respiratory Research 2(2):71-79 (2001).
Griffiths et al., The EMBO Journal 12(2):725-734 (1993).
Holliger et al., Proc Natl Acad Sci USA 90:6444-6448 (1993).
Huston et al., Proc Natl Acad Sci USA 85:5879-5883 (1988).
Ill et al., Protein Engineering 10(8):949-957 (1997).
Kostelny et al., The Journal of Immunology 148(5):1547-1553 (1992).
Kung et al., J Allergy Clin Immunol 94(6):1217-1224 (1994).
Martin et al., The EMBO Journal 13(22):5303-5309 (1994).
Mauser et al., Am J Respir Crit Care Med 152:467-472 (1995).
McCafferty et al., Nature 348:552-554 (1990).
Mendez et al., Nature Genetics 15:146-156 (1997).
Mita et al., Journal of Immunological Methods 125:233-241 (1989).
Poljak, R., Structure 2(12):1121-1123 (1994).
Songsivilai et al., Clin Exp Immunol 79:315-321 (1990).
Traunecker et al., The EMBO Journal 10(12):3655-3659 (1991).
Traunecker et al., Int J Cancer: Supplement 7:51-52 (1992).
Maynard, Jennifer et al., Antibody Engineering, Annu. Rev. Biomed. Eng., vol. 02:339-76 (2000).
Green, Larry L., Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies, Journal of Immunological Methods, vol. 231:11-23 (Dec. 1999).
Dickason, Richard R. et al., Delineation of IL-5 Domains Predicted to Engage the IL-5 Receptor Complex, The Journal of Immunology, vol. 156:1030-1037 (Feb. 1996).
Cornelis, Sigrid et al., Detailed analysis of the IL-5-IL-5Ralpha interaction: characterization of crucial residues on the ligand and the receptor, The EMBO Journal, vol. 14:14, 3395-3402 (Jul. 1995).
Dickason, Richard R. et al., Enhanced detection of human IL-5 in biological fluids utilizing murine monoclonal antibodies which delineate distinct neutralizing epitopes, Cytokine, vol. 6:6, 647-656 (Nov. 1994).
Zhang, Ji et al., Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5, International Immunology, vol. 11:12, 1935-1943 (Dec. 1999).
Griffiths, Andrew D., et al., Isolation of high affinity human antibodies directly from large synthetic repertoires, The EMBO Journal, vol. 13:14, 3245-3260 (Jul. 1994).
Zabeau, Lennart et al., Neutralizing monoclonal antibodies can potentiate IL-5 signaling, Euro. J. Immunol, vol. 31:1087-1097 (Apr. 2001).
Rizzo, Charles A., et al., The IL-5 receptor on human bronchus selectively primes for hyperresponsiveness, J. Allergy Clin. Immunol., vol. 109:404-409 (Mar. 2002).
Corvalan Jose
Greenfeder Scott
Abgenix, Inc.
Mertz Prema
Reed Grant E.
Schering Corporation
LandOfFree
Human monoclonal antibodies to interleukin-5 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibodies to interleukin-5, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies to interleukin-5 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3655405